Navigation Links
United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
Date:7/25/2013

s is presented below (in thousands, except per share data):Three Months Ended June 30,20132012Net income, as reported

$

79,864$

72,316Adjust for non-cash charges:Interest expense

4,5203,879Income tax expense

38,65530,974License fees

——Depreciation and amortization

7,6806,292Impairment charges

—4,839

(1)Share-based compensation expense (benefit)

32,9869,447Earnings before non-cash charges

$

163,705$

127,747Earnings before non-cash charges per share:Basic

$

3.29$

2.42Diluted

$

3.11$

2.37Weighted average number of common shares outstanding:Basic

49,80052,747Diluted

52,64853,942(1)

Consists of a $6.8 million impairment loss relating to a contract-based intangible asset, upon the termination of the underlying license agreement during the three months ending June 30, 2012, net of the $2.0 million of deferred revenue we recognized as a result of the terminated license agreement and the termination of our obligation to perform future services. Conference CallWe will host a half-hour teleconference on Thursday, July 25, 2013, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406 and using access code 9978344.

This teleconference is also being webcast and can be accessed via our website at http://ir.unither.com/events.cfm.

About United TherapeuticsUnited Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

<
'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
4. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
5. Prevagen® is the Number One Branded Memory Supplement in the United States
6. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
8. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
9. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
10. SoundConnect Announces Lync Release in the United States
11. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
(Date:8/28/2014)... NY (PRWEB) August 28, 2014 Whitehouse ... its long term partnership with PTI Inspection Systems ... clients with state of the art leak testing method ... the art instruments currently available. As part of this ... High Voltage Leak Detection Instrument developed and ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised an ... Otter Capital as a significant new partner. Otter Capital’s ... Agriplier™ technology, building on recent compelling field trial results ... meeting, we have been impressed with Otter Capital’s knowledge ... Sobba, President and CEO of GGI. “We look forward ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... YORK, Nov. 6 Morria Biopharmaceuticals,Plc, a biopharmaceutical ... data from its ICH compliant Phase II equivalent,multi-center ... allergic,rhinitis. MRX-4 was given as an intranasal spray ... was conducted in allergic,rhinitis patients outside of the ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a worldwide ... a conference call on Thursday, November 13,2008, at ... and operating,performance for its first fiscal quarter ended ... product development and marketing activities., Corgenix invites ...
... ... flavor enhancer may be used in beverages, foods and oral care ... to reduce the need for sucralose, SAN DIEGO, CA AND ... a leading company,focused on using proprietary technologies to discover and develop ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5
(Date:8/27/2014)... may not be getting effective doses of the HIV ... The initial dosing studies, completed before the drug was ... a protein that is key to removing maraviroc from ... maximum levels of the protein including nearly half ... their bodies compared to those who lack the protein ...
(Date:8/27/2014)... manipulating neural circuits in the brain of mice, ... memories. The research, led by Howard Hughes Medical ... of Technology (MIT), reveals that the connections between ... information about an experience and the part of ... that experience are malleable. , Altering those ...
(Date:8/27/2014)... listen carefully to someone, the first thing we do ... stop moving altogether. This strategy helps us hear better ... , This interplay between movement and hearing also has ... has long suggested that the brain,s motor cortex, which ... rise to our conscious perception of sound. , A ...
Breaking Biology News(10 mins):Dosage of HIV drug may be ineffective for half of African-Americans 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3
... Research Hospital have discovered that a certain differentiated cell ... it requires the constant expression of a gene called ... that Prox1 acts as a two-way switch whose inactivity ... called a lymphatic endothelial cell (LEC). In the absence ...
... and then presented with a chemoattractant signal like cAMP, individual ... a migrating stream. This is the first step in a ... organism. Kriebel et al. show how this streaming response is ... issue of the Journal of Cell Biology ( ...
... deformity known as pectus excavatum corrected report improved body ... published December in the journal Pediatrics . ... telephone interviews of more than 200 patients between the ... surgery. Researchers interviewed parents as well. The ...
Cached Biology News:Reprogrammable cell type depends on a single gene to keep its identity 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 3
Request Info...
NATIVE RAT OSTEOCALCIN...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Biology Products: